• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Precision for Medicine acquires Hobart Group Holdings

Precision for Medicine acquires Hobart Group Holdings

March 26, 2014
CenterWatch Staff

Precision for Medicine, formed in 2012 to support next-generation approaches to drug development and commercialization, has acquired Hobart Group Holdings, a market access firm.

"A primary aim of Precision is to improve the value proposition of medical products and ultimately improve patient outcomes," said Ethan Leder, CEO of Precision. "With the acquisition of Hobart, we continue to build a unique service offering that integrates evidence generation, analytics and communications to address the needs of the patient-centric, multi-payer landscape that characterizes modern healthcare."

Hobart was founded in 2003 and has grown into a managed markets firm dedicated exclusively to product value. The company supports more than 60 biopharmaceutical brands. Hobart’s service model combines deep in-house subject matter experience across payer, provider and distribution systems with state-of-the-art content creation and delivery.

Dan Renick, RPh, president of Hobart and newly named co-president of Precision, said, "Demonstrating value is increasingly complex as required metrics shift from large populations to individual patients, and payers work to address the needs of consumers, health insurance exchanges, integrated delivery systems and accountable care entities. Bridging the value gap that often exists between the pharmaceutical and life sciences industry and its customers requires next-generation approaches to scientific evidence, analytics and communications. Precision is ideally positioned to help clients address these issues, creating a positive impact for healthcare consumers everywhere."

Lisa B. Bair, founder of Hobart, has left the company.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing